Patients with non-metastatic HSPC prefer ARPI-based therapy over androgen deprivation alone

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension

Cabozantinib shows clinical benefit in refractory GCT with over 40% disease control

Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves pathological and DFS outcomes in MIBC

Neoadjuvant cabozantinib plus nivolumab before cytoreductive nephrectomy shows promising responses in metastatic clear cell RCC

ASCO GU 2026: Updates in metastatic prostate cancer

ASCO GU 2026: Updates in localised prostate cancer

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance

Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer

Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma

Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies

Extreme heat exposure around diagnosis is linked to higher mortality in multiple myeloma